NYSE$BAX
Baxter International Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported fourth-quarter and full-year results, reflecting growth in sales and earnings per share driven by sustained demand and the acquisition of Hillrom.
Baxter International Inc. reported a 10% increase in fourth-quarter sales, reaching $3.5 billion, and a 42% increase in U.S. GAAP earnings per share to $0.47. The results include 19 days of contribution from Hillrom following its acquisition in December 2021. The company's performance reflects strong demand for its medically essential products and the impact of its ongoing transformation.
- Fourth-quarter sales increased 10% on a reported basis, 12% on a constant currency basis, and 4% on an operational basis.
- U.S. GAAP earnings per share (EPS) were $0.47, and adjusted EPS was $1.04 for the fourth quarter.
- Full-year revenue increased 10% on a reported basis, 7% on a constant currency basis, and 5% on an operational basis.
- The acquisition of Hillrom is expected to accelerate top- and bottom-line performance and drive innovation in connected care solutions.
Headline financials
Revenue & EPS history
Baxter · Revenue · Quarterly
$3.51B
Revenue by segment
Baxter · $597M total across 2 segments · Q3 2023
- Pharmaceuticals$580M—97.2%
- Other$17M—2.8%
Forward guidance
Baxter expects full-year 2022 sales growth of 24% to 25% on a reported basis and adjusted earnings of $4.25 to $4.35 per diluted share. For the first quarter of 2022, the company anticipates sales growth of 24% to 25% on a reported basis and adjusted earnings of $0.79 to $0.82 per diluted share.
Tailwinds
- Sales growth of 24% to 25% on a reported basis for full-year 2022.
- Adjusted earnings of $4.25 to $4.35 per diluted share for full-year 2022.
- Sales growth of 24% to 25% on a reported basis for first-quarter 2022.
- Adjusted earnings of $0.79 to $0.82 per diluted share for first-quarter 2022.
- Operational sales growth of approximately 4% for full-year 2022.
Headwinds
- Hillrom is expected to negatively impact sales growth by (25)% - (26)% in Q1 2022
- Hillrom is expected to negatively impact sales growth by (22)% - (23)% in FY 2022
- Foreign exchange is expected to positively impact sales growth by 3% in Q1 2022
- Foreign exchange is expected to positively impact sales growth by 2% in FY 2022
- Actual U.S. GAAP earnings per share for the first quarter and full year of 2022 may differ significantly from those amounts.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
47%
34 / 72 earnings
Positive
+18.2%
Q4 2019
Best reaction
-16.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.1% | -0.9% | +11.2% | |
| Q4 2025 | -16.0% | -6.9% | -21.9% | |
| Q3 2025 | -14.4% | -20.0% | -16.4% | |
| Q1 2025 | -1.6% | -4.0% | -2.1% | |
| Q4 2024 | +8.5% | +16.6% | +7.7% | |
| Q3 2024 | -5.0% | -9.5% | -11.8% | |
| Q2 2024 | +5.6% | +7.2% | +12.1% | |
| Q1 2024 | -8.6% | -10.5% | -15.5% | |
| Q4 2023 | +0.4% | +0.6% | +11.1% | |
| Q3 2023 | +3.6% | +4.3% | +11.5% | |
| Q2 2023 | -4.0% | -8.1% | -15.2% | |
| Q1 2023 | +3.5% | +2.0% | -10.4% | |
| Q4 2022 | -10.4% | -12.6% | -16.8% | |
| Q3 2022 | -4.6% | -6.7% | -2.8% | |
| Q2 2022 | -12.2% | -11.9% | -14.4% | |
| Q1 2022 | -0.0% | +1.4% | +7.2% | |
| Q4 2021 | -3.3% | -0.8% | -7.1% | |
| Q3 2021 | -3.6% | -2.0% | -6.9% | |
| Q2 2021 | -5.6% | -6.9% | -9.7% | |
| Q1 2021 | -1.5% | +0.5% | -5.6% | |
| Q4 2020 | +0.0% | -0.4% | +1.0% | |
| Q3 2020 | -0.7% | -1.1% | -2.8% | |
| Q2 2020 | -4.8% | -10.6% | -5.2% | |
| Q1 2020 | -4.0% | -3.0% | -1.6% | |
| Q4 2019 | +18.2% | +5.8% | +26.5% | |
| Q3 2019 | +18.2% | +5.8% | +26.5% | |
| Q2 2019 | +1.5% | +2.7% | +1.3% | |
| Q1 2019 | -0.1% | +0.0% | -1.5% | |
| Q4 2018 | +0.6% | +0.5% | +5.7% | |
| Q3 2018 | -8.1% | -9.0% | -0.2% | |
| Q2 2018 | -6.3% | -5.3% | -5.4% | |
| Q1 2018 | +5.5% | +5.5% | +9.0% | |
| Q4 2017 | -4.8% | -7.4% | -8.0% | |
| Q3 2017 | +0.9% | +0.3% | -0.4% | |
| Q2 2017 | -2.8% | -2.6% | -0.9% | |
| Q1 2017 | +4.2% | +4.5% | +10.2% | |
| Q4 2016 | +0.5% | +0.9% | +6.3% | |
| Q3 2016 | -2.1% | -2.6% | -3.9% | |
| Q2 2016 | +4.8% | +4.2% | +2.2% | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.6% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +5.0% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | -3.0% | — | — | |
| Q3 2013 | -2.3% | — | — | |
| Q2 2013 | +1.3% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.1% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +1.8% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -2.7% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q4 2010 | -1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2009 | +0.9% | — | — | |
| Q1 2010 | -0.8% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q2 2008 | +2.2% | — | — | |
| Q2 2009 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro